Диссертация (1335876), страница 54
Текст из файла (страница 54)
– 2006. – Vol. 6,№ 1. – P. 75-83.315181.Common terminology criteria for adverse events (CTCAE) [Text] : Version4.0. Published May 28, 2009 (v4.03: June 14, 2010) / U.S. Dept. of Health andHuman Services, National Institutes of Health, National Cancer Institute. –[Bethesda, Md.], 2009 [i.e. 2010]. – 194 p.182.Concurrent chemotherapy and pelvic radiation therapy compared with pelvicradiation therapy alone as adjuvant therapy after radical surgery in high-risk earlystage cancer of the cervix [Text] / W.A. Peters 3rd, P.Y.
Liu, R.J. Barrett 2nd [etal.] // J. Clin. Oncol. – 2000. – Vol. 18, № 8. – P. 1606-1613.183.Concurrent cisplatin-based radiotherapy and chemotherapy for locallyadvanced cervical cancer [Text] / P.G. Rose, B.N. Bundy, E.B. Watkins [et al.] //N. Engl. J. Med. – 1999. – Vol. 340, № 15. – P. 1144-1153.184.Contemporary clinical management of endometrial cancer [Text] /H.E. Dinkelspiel, J.D. Wright, S.N. Lewin [et al.] // Obstet.
Gynecol. Int. –2013. – Vol. 2013. – Art. 583891.185.Cramer, D.W. The epidemiology of endometrial and ovarian cancer [Text] /D.W. Cramer // Hematol. Oncol. Clin. North Am. – 2012. – Vol. 26, № 1. – P. 112.186.Cronin, K.A. Sustained lower rates of breast cancer in the United States[Text] / K.A. Cronin, P.M.
Ravdin, B.K. Edwards // Breast Cancer Res Treat. –2009. – Vol. 117, № 1. – P. 223-224.187.Cuschieri, K.S. Human papillomavirus mRNA and p16 detections asbiomarkers for the improved diagnosis of cervical neoplasia [Text] /K.S. Cuschieri, N. Wentzensen // Cancer Epidemiol. Biomarkers Prev. – 2008. –Vol. 17, № 10. – P. 2536-2545.188.Cust, A.E. Physical activity and gynecologic cancer prevention [Text] /A.E. Cust // Recent Results Cancer Res. – 2011. – Vol. 186. – P. 159-185.189.Decrease in breast cancer incidence following a rapid fall in use of hormonereplacement therapy in Australia [Text] / K. Canfell, E.
Banks, A.M. Moa [et al.] //Med. J. Aust. – 2008. – Vol. 188, № 11. – P. 641-644.316190.Determining of prognostic factors in gastric cancer patients using artificialneural networks [Text] / A. Biglarian, E. Hajizadeh, A. Kazemnejad[et al.] // Asian. Pac. J. Cancer. Prev. – 2010. – Vol.
11, № 2. – P. 533-536.191.Disparities in breast cancer mortality trends between 30 European countries:retrospective trend analysis of WHO mortality database [Electronic resource] /P. Autier, M. Boniol, C. La Vecchia [et al.] // BMJ. – 2010. – Vol. 341. – c3620. –Mode of access: http://www.bmj.com/content/341/bmj.c3620.192.Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlledtrial [Text] / N. Katsumata, M.
Yasuda, F. Takahashi [et al.] // Lancet. – 2009. –Vol. 374, № 9698. – P. 1331-1338.193.Early stage I adenocarcinoma of the uterine cervix: treatment results inpatients with tumors less than or equal to 4 cm in diameter [Text] / P.J. Eifel,T.W. Burke, L. Delclos [et al.] // Gynecol. Oncol. – 1991. – Vol. 41, № 3.
– P. 199205.194.Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNAtesting in primary cervical cancer screening [Text] / P. Naucler, W. Ryd,S. Tornberg [et al.] // J. Natl. Cancer. Inst. – 2009. – Vol. 101, № 2. – P. 88-99.195.Endometrial cancer incidence trends in Europe: underlying determinants andprospects for prevention [Text] / F.
Bray, I. Dos Santos Silva, H. Moller [et al.] //Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14, № 5. – P. 1132-1142.196.Estimates of worldwide barden of cancer in 2008: GLOBOCAN 2008 [Text] /J. Ferlay, H.R. Shin, F. Bray [et al.] // Int. J. Cancer. – 2010. – Vol. 127, № 12. –P.
2893-2917.197.EUROCARE-3: survival of cancer patients diagnosed 1990-94–results andcommentary [Text] / M. Sant, T. Aareleid, F. Berrino [et al.] // Ann. Oncol. –2003. – Vol. 14, suppl. 5. – P. v61- v118.198.European guidelines on cardiovascular disease prevention in clinicalpractice: executive summary. Fourth Joint Task Force of the European Society ofCardiology and other societies on cardiovascular disease prevention in clinical317practice [Text] // Eur.
J. Cardiovasc. Prev. Rehabil. – 2007. – Vol. 14, suppl. 2. –P. S1- S113.199.Evaluation of new platinum-based treatment regimens in advanced-stageovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup [Text] /M.A. Bookman, M.F. Brady, W.P. McGuire [et al.] // J. Clin. Oncol. – 2009. –Vol. 27, № 9. – P. 1419-1425.200.Evidence-based, alternative cervical cancer screening approaches in low-resource settings [Text] / J.
Sherris, S. Wittet, A. Kleine [et al.] // Int. Perspect. Sex.Reprod. Health. – 2009. – Vol. 35, № 3. – P. 147-154.201.First-line treatment of ovarian cancer FIGO stages IIb-IV withpaclitaxel/epirubicin/carboplatinversuspaclitaxel/carboplatin[Text]/G.B. Kristensen, I. Vergote, G. Stuart [et al.] // Int. J. Gynecol. Cancer. – 2003. –Vol.
13, suppl 2. – P. 172-177.202.Friberg, E. Diabetes and risk of endometrial cancer: a population-basedprospective cohort study [Text] / E. Friberg, C.S. Mantzoros, A. Wolk // CancerEpidemiol. Biomarkers Prev. – 2007. – Vol. 16, № 2. – P. 276-80.203.Genomic alterations in cervical carcinoma: losses of chromosomeheterozygosity and human papilloma virus tumor status [Text] / M. Millokandov,N. Kholodilov, N. Atkin [et al.] // Cancer Res. – 1996. – Vol. 56, № 1. – P. 197205.204.Global cancer statistics, 2002 [Text] / D.M. Parkin, F. Bray, J.
Ferlay[et al.] // CA. Cancer. J. Clin. – 2005. – Vol. 55, № 2. – P. 74-108.205.Global patterns of cancer incidence and mortality rates and trends[Text] / A. Jemal, M.M. Center, C. Desantis [et al.] // Cancer EpidemiolBiomarkers Prev. – 2010. – Vol. 19, № 8. – P. 1893-1907.206.Global trends in breast cancer incidence and mortality 1973-1997[Text] / M.D. Althuis, J.D. Dozier, W.F. Anderson [et al.] // Int. J. Epidemiol. –2005. – Vol. 34, № 2. – P. 405-412.318207.GLOBOCAN 2008 : Cancer incidence and mortality worldwide [Electronicresource] / eds.: J.
Ferlay, H.R. Shin, F. Bray [et al.]. – Lyon : IARC Press,2010. – 1 CD-ROM. – (IARC Cancer Base ; № 10).208.Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit2007 [Text] / B.O. Anderson, C.H. Yip, R.A. Smith [et al.] // Cancer. – 2008. –Vol. 113, 8 suppl. – P. 2221-2243.209.Hausen,H.Humanpapillomaviruses[Text]/H.zurHausen,E.-M. de Villers // Аnnu.
Rev. Microbiol. – 1994. – Vol. 48. – P. 427-447.210.High resolution mapping of chromosome 6 deletions in cervical cancer[Text] / N. Mazurenko, M. Attaleb, T. Gritzko [et al.] // Oncol. Rep. – 1999. –Vol. 6, № 4. – P. 321-328.211.Hopkins, M.P. The prognosis and management of cervical cancer associatedwith pregnancy [Text] / M.P. Hopkins, G.W. Morley // Obstet. Gynecol. – 1992. –Vol. 80, № 1. – P. 9-13.212.HPVscreeningforcervicalcancerinruralIndia[Text]/R. Sankaranarayanan, B.M.
Nene, S.S. Shastri [et al.] // N. Engl. J. Med. – 2009. –Vol. 360, № 14. – P. 1385-1394.213.Hulka, B.S. Breast cancer: hormones and other risk factors [Text] /B.S. Hulka, P.G. Moorman // Maturitas. – 2001. – Vol. 38, № 1. – P. 103-113.214.Human papilloma virus (HPV) DNA associated with prognosis of cervicalcancer after radiotherapy [Text] / Y. Harima, S. Sawada, K. Nagata [et al.] // Int. J.Radiat. Oncol. Biol. Phys. – 2002.
– Vol. 52, № 5. – Р. 1345-1351.215.Hunter, M.I. Cervical neoplasia in pregnancy. Part 2: current treatment ofinvasive disease [Text] / M.I. Hunter, K. Tewari, B.J. Monk // Am. J. Obstet.Gynecol. – 2008. – Vol. 199, № 1. – P. 10-18.216.Hypertension and hormone-related neoplasms in women [Text] / M. Soler,L. Chatenoud, E. Negri [et al.] // Hypertension. – 1999.
– Vol. 34, № 2. – P. 320325.319217.Impact of adjuvant chemotherapy and surgical staging in early-stage ovariancarcinoma: European Organisation for Research and Treatment of CancerAdjuvant ChemoTherapy in Ovarian Neoplasm trial [Text] / J.B. Trimbos,I. Vergote, G.
Bolis [et al.] // J. Natl. Cancer Inst. – 2003. – Vol. 95, № 2. – P. 113125.218.Impact on survival of surgically defined favorable responses to salvageintraperitoneal chemotherapy in small-volume residual ovarian cancer [Text] /M. Markman, B. Reichman, T. Hakes [et al.] // J. Clin. Oncol. – 1992.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
